Zobrazeno 1 - 6
of 6
pro vyhledávání: '"Cathrine L Denton"'
Autor:
John K Thuita, Michael Z Wang, John M Kagira, Cathrine L Denton, Mary F Paine, Raymond E Mdachi, Grace A Murilla, Shelley Ching, David W Boykin, Richard R Tidwell, James E Hall, Reto Brun
Publikováno v:
PLoS Neglected Tropical Diseases, Vol 6, Iss 7, p e1734 (2012)
Novel drugs to treat human African trypanosomiasis (HAT) are still urgently needed despite the recent addition of nifurtimox-eflornithine combination therapy (NECT) to WHO Model Lists of Essential Medicines against second stage HAT, where parasites h
Externí odkaz:
https://doaj.org/article/dba01f043eb542fabcb25c6cfc47a593
Autor:
Samuel C. Blackman, Stanley W. Carson, Graeme Young, Chao Han, Lauren E. Richards-Peterson, Royce A. Morrison, Elisabeth A. Minthorn, Jeffrey Botbyl, Daniele Ouellet, Cathrine L. Denton
Publikováno v:
The Journal of Clinical Pharmacology. 53:955-961
Dabrafenib is an orally bioavailable, potent, and selective inhibitor of human wild-type BRAF and CRAF kinases as well as mutant forms of BRAF kinase. The aim of this phase 1, single-center, open-label study in four patients with BRAF mutation-positi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::8e992dbc8e06cc2e70e22b138e42307f
https://doi.org/10.1002/jcph.127
https://doi.org/10.1002/jcph.127
Publikováno v:
Cancer Chemotherapy and Pharmacology. 67:349-360
AZD6244 (ARRY-142886) (AstraZeneca, Macclesfield, UK) is a novel small molecule MEK1/2 inhibitor that is currently being tested in Phase II trials. With the recent publication of human pharmacokinetic data from clinical studies, we now know the achie
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::528004b0561b219c5412e0dd57df4235
https://doi.org/10.1007/s00280-010-1323-z
https://doi.org/10.1007/s00280-010-1323-z
Autor:
Cathrine L, Denton, Elisabeth, Minthorn, Stanley W, Carson, Graeme C, Young, Lauren E, Richards-Peterson, Jeffrey, Botbyl, Chao, Han, Royce A, Morrison, Samuel C, Blackman, Daniele, Ouellet
Publikováno v:
Journal of clinical pharmacology. 53(9)
Dabrafenib is an orally bioavailable, potent, and selective inhibitor of human wild-type BRAF and CRAF kinases as well as mutant forms of BRAF kinase. The aim of this phase 1, single-center, open-label study in four patients with BRAF mutation-positi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::e67bd75a40243df48c9b946133468a74
https://pubmed.ncbi.nlm.nih.gov/23846776
https://pubmed.ncbi.nlm.nih.gov/23846776
Autor:
Reto Brun, Mary F. Paine, John K. Thuita, Cathrine L. Denton, R. E. Mdachi, Shelley Ching, Grace Murilla, Richard R. Tidwell, John Kagira, David W. Boykin, James Edwin Hall, Michael Zhuo Wang
Publikováno v:
PLoS Neglected Tropical Diseases, Vol 6, Iss 7, p e1734 (2012)
PLoS Neglected Tropical Diseases
PLoS Neglected Tropical Diseases
Novel drugs to treat human African trypanosomiasis (HAT) are still urgently needed despite the recent addition of nifurtimox-eflornithine combination therapy (NECT) to WHO Model Lists of Essential Medicines against second stage HAT, where parasites h
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7a97f7ebdcf1a4b86d5830b7463ee615
https://edoc.unibas.ch/28062/
https://edoc.unibas.ch/28062/
Autor:
Cathrine L. Denton, Samuel C. Blackman, Royce A. Morrison, Daniele Ouellet, Stanley W. Carson, Graeme Young, Lauren E. Richards-Peterson, Jeffrey Botbyl
Publikováno v:
Cancer Research. 72:3773-3773
Background. Absolute bioavailability (BA) studies in oncology are logistically and technically challenging. Use of an intravenous (IV) microtracer offers an attractive alternative to conventional cross-over design studies. This method involves concom
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::a8603866728aaffffddaef89578f0104
https://doi.org/10.1158/1538-7445.am2012-3773
https://doi.org/10.1158/1538-7445.am2012-3773